Adaptation of Mia® (Mammography Intelligence Assessment) to support breast screening programmes to address Covid-19-related breast screening backlog

由于2019冠状病毒病的爆发，NHS的多项常规服务暂停，包括乳房筛查项目。据估计，妇女接受筛查的时间延迟3-9个月，将导致更多的癌症在更容易治疗的阶段被遗漏，并给已经负担过重的系统带来巨大压力。我们的乳腺癌筛查人工智能解决方案Mia（乳房x线照相术智能评估）可以通过自动化乳房筛查计划的某些方面，同时保持当前的筛查性能标准，帮助解决这一迫在眉睫的危机。我们已经开发了一种分阶段的方法，与人类乳房放射学读卡器进入乳房筛查服务的方式一致，这需要彻底的验证。我们将与乳腺放射科医生一起，在商业化前对Mia进行验证和测试，并建立对人工智能的信任。与我们的NHS合作伙伴一起，我们将开发所需的前瞻性临床证据，以便及时加快Mia的采用，以应对即将到来的危机。该项目的产出将是一个人工智能解决方案，可以快速追踪，以减少Covid-19造成的积压，并为英国每位女性提供更好的抗击乳腺癌的机会。

Due to the Covid-19 outbreak, multiple routine NHS services are on pause, including breast screening programmes. An estimated 3-9 month delay in women being screened will lead to more cancers being missed at the stage where they are easier to treat and immense pressure on an already overburdened system. Our breast cancer screening AI solution Mia (Mammography intelligent assessment) can help solve this impending crisis by automating some aspects of the breast screening programme whilst maintaining current screening performance standards. We have developed a phased approach aligned with the way the human breast radiology readers are brought into the breast screening service and this requires a thorough validation. With breast radiologists, we will validate and test Mia in the pre-commercial period and build trust in the AI. With our NHS partners, we will develop the prospective clinical evidence required for the accelerated adoption of Mia in time to tackle the impending crisis. The output of the project will be an AI solution that can be fast-tracked to reduce the backlogs caused by Covid-19 and give every woman in the UK a better fighting chance against breast cancer.